Ovarialkarzinom: Immuntherapie, quo vadis?Ovarian cancer: immunotherapy, quo vadis?

被引:0
作者
Frederik Marmé
机构
[1] Universität Heidelberg,Experimentelle und Translationale Gynäkologische Onkologie, Konservative Gynäkologische Onkologie, Medizinische Fakultät Mannheim
[2] Universitätsklinikum Mannheim,Frauenklinik, Haus 1, Ebene 1
关键词
D O I
10.1007/s00129-022-04963-0
中图分类号
学科分类号
摘要
引用
收藏
页码:591 / 602
页数:11
相关论文
共 213 条
[1]  
Zhang L(2003)Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 203-213
[2]  
Conejo-Garcia JR(2012)Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis Gynecol Oncol 124 192-198
[3]  
Katsaros D(2017)Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer JAMA Oncol 3 e173290-8331
[4]  
Hwang WT(2012)Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature PLoS One 7 e50946-5026
[5]  
Adams SF(2005)The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer Clin Cancer Res 11 8326-4360
[6]  
Tahirovic E(2005)Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma Cancer Res 65 5020-5434
[7]  
Ovarian Tumor Tissue Analysis C(2012)CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity Cancer Res 72 4351-8905
[8]  
Goode EL(2011)Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer Cancer Res 71 5423-949
[9]  
Block MS(2007)Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma Cancer Res 67 8900-74
[10]  
Zhang QW(2004)Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 942-15